Novltreat 2.4

Noveltreat 2.4mg Injection contains Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is supplied as a single-dose pre-filled pen containing Semaglutide 2.4 mg/0.75 mL and is intended for once-weekly subcutaneous use. Noveltreat 2.4mg Injection is indicated for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. It is used along with a reduced-calorie diet and increased physical activity. It is a prescription medicine and should be used under medical supervision.

Noveltreat 2.4mg Injection may be prescribed for: Chronic weight management: Semaglutide may be used along with a reduced-calorie diet and increased physical activity to help reduce excess body weight and maintain weight reduction in the long term. Weight-related health conditions: It may be prescribed for adults who are overweight or obese and have one or more weight-related health conditions, as determined by the doctor. The dose is selected and adjusted by the doctor based on the individual's response and treatment goals. Do not change the dose without medical advice.

Noveltreat 2.4mg Injection is given as a subcutaneous injection once weekly, exactly as prescribed by your doctor. It can be injected into areas such as the abdomen, thigh, or upper arm. Rotate the injection site when possible. The product is supplied as a single-dose pre-filled pen designed to deliver 2.4 mg of Semaglutide. Your doctor or healthcare professional should show you how to use the pen before your first injection. Do not inject it into a vein or muscle.

Common side effects of Noveltreat 2.4mg Injection may include: Nausea Vomiting Diarrhoea Constipation Abdominal pain Reduced appetite Headache Fatigue These effects may be more common when treatment is started or the dose is increased and may improve as the body adjusts. Seek medical attention if you develop severe or persistent abdominal pain, particularly if it spreads to the back, as this may be a sign of pancreatitis. Gallbladder-related problems can also occur with Semaglutide treatment.

Pregnancy Unsafe Noveltreat should not be used during pregnancy unless specifically advised by a doctor. If you become pregnant while using Semaglutide, contact your doctor promptly. Women planning a pregnancy should discuss treatment with their doctor beforehand. Semaglutide should generally be stopped at least 2 months before a planned pregnancy because it remains in the body for a prolonged period. Breast Feeding Consult Your Doctor Tell your doctor if you are breastfeeding before using Noveltreat 2.4mg Injection. Your doctor will decide whether treatment is appropriate based on your individual circumstances. Lungs Consult Your Doctor Semaglutide does not have specific routine lung-related precautions. Tell your doctor about any significant respiratory condition and inform your healthcare team if you are scheduled for surgery or a procedure requiring general anaesthesia or deep sedation. Liver Consult Your Doctor Tell your doctor if you have liver disease before starting Noveltreat 2.4mg Injection. Your doctor will decide whether any additional monitoring or treatment adjustments are needed. Alcohol Consult Your Doctor Alcohol may worsen gastrointestinal symptoms such as nausea

2 - 8°C